OLSALAZINE manufacturers
- OLSALAZINE USP/EP/BP
-
- $1.10 / 1g
-
2021-08-03
- CAS:15722-48-2
- Min. Order: 1g
- Purity: 0.999
- Supply Ability: 100 Tons min
- Olsalazine
-
- $1.00 / 1g
-
2021-07-20
- CAS:15722-48-2
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- OLSALAZINE
-
- $1.00 / 1KG
-
2020-01-05
- CAS:15722-48-2
- Min. Order: 1KG
- Purity: 95-99%
- Supply Ability: 1ton
|
| | OLSALAZINE Basic information |
| Product Name: | OLSALAZINE | | Synonyms: | Ph-CJ-91B;4,4'-Dihydroxyazobenzene-3,3'-dicarboxylic acid;5,5'-Azodisalicylic acid;3,3'-(1,2-diazenediyl)bis[6-hydroxy-Benzoic acid;OLSALAZINE;3,3’-azobis(6-hydroxy-benzoicaci;3,3’-azobis(6-hydroxybenzoicacid);5,5’-azobis(salicylicacid) | | CAS: | 15722-48-2 | | MF: | C14H10N2O6 | | MW: | 302.24 | | EINECS: | 605-089-5 | | Product Categories: | | | Mol File: | 15722-48-2.mol |  |
| | OLSALAZINE Chemical Properties |
| Melting point | >300 °C(Solv: acetic acid (64-19-7); water (7732-18-5)) | | Boiling point | 443.29°C (rough estimate) | | density | 1.3578 (rough estimate) | | refractive index | 1.6500 (estimate) | | pka | 2.40±0.10(Predicted) | | Water Solubility | 11.49ug/L(25 ºC) | | CAS DataBase Reference | 15722-48-2(CAS DataBase Reference) |
| | OLSALAZINE Usage And Synthesis |
| Uses | Anti-inflammatory (gastrointestinal). | | Definition | ChEBI: An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease. | | Indications | Olsalazine is approved for maintenance of remission
of ulcerative colitis, but a commonly reported
side effect is a paradoxical increase in diarrhea. The
U. S. Food and Drug Administration (FDA) has approved
balsalazide disodium (Colazal) as a treatment of
mild to moderately active ulcerative colitis. | | Brand name | Dipentum (UCB). | | Mechanism of action | Olsalazine is approved for maintenance of remission
of ulcerative colitis, but a commonly reported
side effect is a paradoxical increase in diarrhea. The
U. S. Food and Drug Administration (FDA) has approved
balsalazide disodium (Colazal) as a treatment of
mild to moderately active ulcerative colitis. | | Veterinary Drugs and Treatments | Olsalazine is used for treatment of dogs with chronic colitis that either
cannot tolerate the adverse effects associated with sulfasalazine
or the response to sulfasalazine has been ineffective. |
| | OLSALAZINE Preparation Products And Raw materials |
|